FDA Commissioner announces Navigator expansion to Rare Diseases

In one powerful blog post, Dr. Gottlieb waives requirements to wait for a full convening of IRBs to approve single patient expanded access treatments, announces the future expansion of the Foundation's Navigator to rare diseases and offers clarity on which adverse events during EA treatment need to be submitted to FDA.